General Updates

Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji T +91 22 6060 9000 Road, Chakala, Andheri (E), E legal.info@ajantapharma.com Mumbai 400 093, India W www.ajantapharma.com 2nd July 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 051 Mumbai – 400001 Scrip Code: AJANTPHARM EQ Scrip Code: AJANTPHARM 532331 Sub.: Update on US FDA inspection at Paithan manufacturing facility Dear Sir/Madam, We are pleased to inform you that the Company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility at Paithan, Maharashtra. The inspection has been classified as Voluntary Action Indicated (VAI). The current Good Manufacturing Practices (cGMP) inspection of the Paithan facility was conducted by the USFDA from 13 April 2026 to 21 April 2026. The Company had earlier intimated the stock exchanges regarding the inspection on 22 April 2026. This is for your information and records. Thanking you, Yours faithfully, Gaurang Shah Sr. VP – Legal & Company Secretary Corporate Identity Number - L24230MH1979PLC022059